Other Species / Isoforms
  S100A9 (human)      LTP 

LTP (Low Throughput Papers) : The number of records in which this modification site was determined using methods other than discovery mass spectrometry.

 HTP 

HTP (High Throughput Papers): The number of records in which this modification site was assigned using ONLY proteomic discovery mass spectrometry.

 
S6
__MTCKMSQLERNIE
0 1
S100A9 (human) __MTCKMSQLERNIE S6
S100A9 (mouse) _MANKAPsQMERSIT S7-p
S100A9 (rat) _MAAKTGSQLERSIS S7
S23-p
INTFHQYsVKLGHPD
0 1
S100A9 (human) INTFHQYsVKLGHPD S23-p
S100A9 (mouse) IDTFHQYSRKEGHPD S24
S100A9 (rat) INVFHQYSRkYGHPD S24
K25
TFHQYsVKLGHPDtL
0 1
S100A9 (human) TFHQYsVKLGHPDtL K25
S100A9 (mouse) TFHQYSRKEGHPDtL K26
S100A9 (rat) VFHQYSRkYGHPDTL K26-ac
T31-p
VKLGHPDtLNQGEFk
Upstream
0 3
Treatment
  • anti-CD3
S100A9 (human) VKLGHPDtLNQGEFk T31-p
S100A9 (mouse) RKEGHPDtLSkKEFR T32-p
S100A9 (rat) RkYGHPDTLNKAEFK T32
Q34
GHPDtLNQGEFkELV
0 1
S100A9 (human) GHPDtLNQGEFkELV Q34
S100A9 (mouse) GHPDtLSkKEFRQMV K35-ac
S100A9 (rat) GHPDTLNKAEFKEMV K35
K38-ac
tLNQGEFkELVRKDL
0 4
S100A9 (human) tLNQGEFkELVRKDL K38-ac
S100A9 (mouse) tLSkKEFRQMVEAQL R39
S100A9 (rat) TLNKAEFKEMVNKDL K39
N47
LVRKDLQNFLKKENK
0 1
S100A9 (human) LVRKDLQNFLKKENK N47
S100A9 (mouse) MVEAQLAtFMKKEKR T48-p
S100A9 (rat) MVNKDLPNFLKREKR N48
T68-p
HIMEDLDtNADKQLS
Upstream
0 1
Treatment
  • anti-CD3
S100A9 (human) HIMEDLDtNADKQLS T68-p
S100A9 (mouse) DIMEDLDTNQDNQLS T69
S100A9 (rat) DIMEDLDTNQDNQLS T69
H105
DEGPGHHHKPGLGEG
0 1
S100A9 (human) DEGPGHHHKPGLGEG H105
S100A9 (mouse) PRGHGHShGKGCGK_ H107-me
S100A9 (rat) PRGHDHSHGKGCGK_ H107
T113-p
KPGLGEGtP______
Upstream
Downstream
4 36
Effects on Modified Protein
  • activity, induced
  • intracellular localization
Effects on Biological Processes:
  • cytoskeletal reorganization
Kinase, in vitro:
  • P38A (human)
Treatment
  • ionomycin
  • phorbol_ester
  • PI-103
S100A9 (human) KPGLGEGtP______ T113-p
S100A9 (mouse) gap -
S100A9 (rat) gap -